Cabozantinib as first-line treatment in advanced renal cell carcinoma: a profile of its use
- 79 Downloads
Oral cabozantinib tablets (Cabometyx®) are an important option for the treatment of advanced renal cell carcinoma (RCC). Cabozantinib is an anti-angiogenic agent and potently inhibits multiple tyrosine kinases, including those implicated in the development of RCC. The previously approved indication of cabozantinib tablets (i.e. treatment of advanced RCC following prior VEGF-targeted therapy) has been extended to include the first-line treatment of advanced RCC in treatment-naïve adults with intermediate or poor risk (EU) and all patients with advanced RCC (USA). These label extensions are based on the results of a randomized, open-label phase 2 trial, in which adults with metastatic RCC of poor or intermediate risk received targeted first-line treatment with cabozantinib or standard-of-care sunitinib. Relative to sunitinib, cabozantinib significantly prolonged median progression-free survival (primary endpoint; investigator and independent assessments), and increased the objective response rate (investigator assessment). The tolerability profile of cabozantinib is comparable to those of other tyrosine kinase inhibitors, with adverse events being manageable with medical intervention, dosage reductions, treatment interruption and/or permanent discontinuation.
The manuscript was reviewed by: E. Gallardo, Medical Oncology Department, Parc Taulí Hospital Universitari, Institut d’Investigació i Innovació ParcTaulí I3P, Universitat Autònoma de Barcelona, Sabadell, Spain; B. Maughan, Department of Oncology, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. During the peer review process, Ipsen Pharma (EU) and Exelixis, Inc. (USA), the marketing-authorization holders of cabozantinib, were also offered an opportunity to provide a scientific accuracy review of their data. Changes resulting from comments received were made on the basis of scientific and editorial merit.
Compliance with ethical standards
The preparation of this review was not supported by any external funding.
Conflicts of interest
K. A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.
- 1.National Comprehensive Cancer Network®. Clinical Practice Guidelines in Oncology (NCCN Guidelines®): kidney cancer (version 4.2018). Fort Washington: National Comprehensive Cancer Network®, Inc.; 2018.Google Scholar
- 7.Cabometyx® (cabozantinib) 20, 40 and 60 mg oral tablets: summary of product characteristics. London: European Medicines Agency; 2018.Google Scholar
- 8.Cabometyx® (cabozantinib) 20, 40 and 60 mg tablets, for oral use: US prescribing Information. South San Francisco: Exelixis, Inc.; 2017.Google Scholar
- 9.Cometriq® (cabozantinib) 20 and 80 mg capsules: summary of product characteristics. London: European Medicines Agency; 2018.Google Scholar
- 10.Cometriq® (cabozantinib) 20 and 80 mg capsules, for oral use: US prescribing Information. South San Francisco: Exelixis, Inc.; 2018.Google Scholar
- 20.Nguyen L, Holland J, Miles D, et al. Pharmacokinetic (PK) drug interaction studies of cabozantinib: effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK. J Clin Pharmacol. 2015;55(9):1012–23.CrossRefGoogle Scholar
- 21.Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–7 [erratum J Clin Oncol. 2017;35(32):3736].CrossRefGoogle Scholar
- 22.Choueiri TK, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;94:115–25.CrossRefGoogle Scholar
- 23.Feldman DR, Feuilly M, Meng J, et al. ECOG score analysis as a proxy for health-related quality of life assessment in patients with poor or intermediate risk metastatic renal cell carcinoma from the CABOSUN trial (Alliance A031203) [abstract no. e18690]. J Clin Oncol. 2018;36(Suppl).CrossRefGoogle Scholar
- 24.Chen RC, Feuilly M, Meng J, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST): analysis of cabozantinib (Cabo) vs sunitinib (Sun) in patients with advanced renal cell carcinoma (aRCC) of intermediate or poor risk (Alliance A031203) [abstract no. 4556]. J Clin Oncol. 2018;36(Suppl).CrossRefGoogle Scholar
- 28.George DJ, Hessel C, Halabi S, et al. Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma (RCC) of intermediate or poor risk: subgroup analysis of progression-free survival (PFS) and objective response rate (ORR) in the Alliance A031203 CABOSUN trial [abstract no. 582]. J Clin Oncol. 2018;36(Suppl 6S).CrossRefGoogle Scholar
- 31.Miles DR, Lacy SA, Wada DR, et al. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes. Cancer Chemother Pharmacol. 2017;80(2):295–306.CrossRefGoogle Scholar